Village Farms(US:VFF)2026-03-12 11:30Financial Performance - Consolidated net income from continuing operations for the full year 2025 reached $21.0 million, or $0.19 per share, with adjusted EBITDA of $49.9 million and operating cash flow of $58.1 million[4]. - Q4 consolidated net sales increased by 9% year-over-year to $49.6 million, with Canadian cannabis sales up 10% and international export cannabis sales soaring by 384%[4]. - Q4 net income from continuing operations improved to $2.3 million, or $0.02 per share, compared to a net loss of $7.5 million in the prior year[4]. - Total sales for the year ended December 31, 2025, reached $215.937 million, with cannabis sales contributing $163.710 million from the U.S. and $26.295 million from Canada[27]. - Net income for the year ended December 31, 2025, was CAD $37.0 million, compared to a loss of CAD $4.8 million in 2024[20]. - The company reported a net loss attributable to shareholders of $32,441,000 for the year, an improvement from a loss of $35,851,000 in 2024[40]. Operational Efficiency - Canadian cannabis gross margin for Q4 was reported at 43%, with adjusted EBITDA of $9.8 million, representing 25.8% of sales[4]. - Adjusted EBITDA from Continuing Operations for Q4 2025 was CAD $14.3 million, compared to a loss of CAD $9.1 million in Q4 2024[20]. - Adjusted EBITDA from continuing operations for the year was $49,852,000, compared to $7,374,000 in 2024, indicating a substantial increase in profitability[40]. - The cost of sales for the same period in 2025 was $30,395,000, compared to $39,886,000 in 2024, indicating a reduction of about 23.9%[25]. - Gross Profit for Q4 2025 was CAD $22.7 million, significantly up from CAD $1.0 million in Q4 2024, reflecting a 2170% increase[20]. Market Expansion - The Delta 2 expansion project commenced cultivation on March 2, 2026, expected to yield an additional 15 tonnes of production capacity in 2026[4]. - The Netherlands expansion is on track, with the first grow rooms expected to be planted by the end of Q1 2026 and full facility completion anticipated by the end of Q2 2026, aiming for an annual production capacity of approximately 10 tonnes[4]. - International export sales increased significantly, driven by strong demand in Germany and other international markets, positioning the company as a leading exporter of medical cannabis to Europe[4]. - The company is focusing on market expansion and new product development to drive future growth, particularly in the cannabis and clean energy sectors[25]. Financial Health - The company ended 2025 with $86 million in cash and has completed $6.7 million in share repurchases since Q3 2025[4]. - Cash and cash equivalents increased to $81,189,000 as of December 31, 2025, up from $24,631,000 in 2024, indicating stronger liquidity[38]. - Total current assets rose to $154,437,000 in 2025, compared to $116,019,000 in 2024, reflecting growth in operational capacity[38]. - The company’s total liabilities decreased to $113,034,000 in 2025 from $125,348,000 in 2024, indicating improved financial health[38]. Strategic Investments - The company is focused on maintaining a balanced approach to capital allocation, considering both organic and acquisitive investments for growth in 2026[4]. - The company anticipates continued growth in the greenhouse vegetable and cannabis sectors, supported by strategic investments and market expansion plans[35]. - The company is focusing on expanding its cannabis production capabilities and exploring new market opportunities in clean energy sectors[27][28]. Challenges and Cautions - The company cautioned that results for the periods ended December 31, 2025, and 2024 may not be indicative of future performance[24]. - The company reported a significant impairment of goodwill and intangible assets amounting to $11.939 million in 2024[28]. - The foreign currency exchange loss for the year ended December 31, 2025, was $1,677,000, compared to a gain of $2,635,000 in 2024, indicating a negative shift in currency impacts[30].